Trevena

OverviewSuggest Edit

Trevena Inc is a clinical stage biopharmaceutical company involved in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. The Company's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena’s pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson’s disease.

TypePublic
Founded2008
HQBerwyn, PA, US
Websitetrevena.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2018)29(-43%)
Job Openings2
Revenue (FY, 2020)$3.1 M(+9800%)
Share Price (Jun 2022)$0.4(-9%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Trevena

Barry Shin

Barry Shin

Senior Vice President, Chief Financial Officer
Mark A. Demitrack

Mark A. Demitrack

Senior Vice President, Chief Medical Officer
Katrine Sutton

Katrine Sutton

Vice President, Finance Planning & Analysis
Michael J. Fossler

Michael J. Fossler

Vice President, Clinical Development and Quantitative Sciences
Show more

Trevena Office Locations

Trevena has an office in Berwyn
Berwyn, PA, US (HQ)
955 Chesterbrook Blvd #110
Show all (1)

Trevena Financials and Metrics

Trevena Revenue

Trevena's revenue was reported to be $3.07 m in FY, 2020
USD

Revenue (Q1, 2021)

209.0k

Gross profit (Q1, 2021)

46.0k

Gross profit margin (Q1, 2021), %

22%

Net income (Q1, 2021)

(9.8m)

EBIT (Q1, 2021)

(10.0m)

Market capitalization (24-Jun-2022)

68.8m

Closing stock price (24-Jun-2022)

0.4

Cash (31-Mar-2021)

97.7m

EV

(28.2m)
Trevena's current market capitalization is $68.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.3m3.8m5.7m31.0k3.1m

Revenue growth, %

(40%)

Cost of goods sold

182.0k

Gross profit

2.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

625.0k1.9m1.9m1.9m1.9m3.0m209.0k

Cost of goods sold

163.0k

Gross profit

46.0k

Gross profit Margin, %

22%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

36.2m46.8m24.3m16.6m32.9m32.3m109.4m

Accounts Receivable

4.1m71.0k

Prepaid Expenses

1.4m607.0k1.7m570.0k

Inventories

669.2k1.9m1.8m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

91.3m81.6m72.2m29.1m43.7m39.0m34.5m36.8m25.2m18.7m14.0m18.1m18.1m24.0m24.3m20.3m23.8m29.3m28.1m54.8m112.7m97.7m

Accounts Receivable

296.0k

Prepaid Expenses

3.4m2.5m924.3k1.7m883.2k986.9k2.5m3.1m1.6m2.9m3.5m2.1m1.8m1.5m1.2m1.6m1.3m2.3m1.7m2.5m1.0m2.6m

Current Assets

94.7m84.2m73.1m102.5m107.3m170.0m166.0m147.6m121.3m100.8m87.7m78.7m63.4m67.3m71.2m61.6m55.3m47.0m29.8m57.2m113.7m109.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(49.7m)(50.5m)(103.0m)(71.9m)(30.8m)(24.9m)(29.4m)

Depreciation and Amortization

239.4k207.9k246.0k490.0k645.0k600.0k477.0k

Inventories

(2.9m)(2.8m)

Accounts Payable

4.2m2.8m7.1m(8.4m)(1.2m)(1.3m)3.4m
USDQ1, 2014

Financial Leverage

1.1 x
Show all financial metrics

Trevena Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Trevena Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Trevena Online and Social Media Presence

Embed Graph

Trevena News and Updates

Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care

CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherap…

Trevena to Participate at the JMP Securities Life Sciences Conference

CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, and…

Trevena to Present at the H.C. Wainwright Global Investment Conference

CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and B…

Trevena Reports First Quarter 2022 Results and Provides Business Update

OLINVYK refocused commercial strategy initiated mid-Q1

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche fro…

Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group

CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the Company entered into a royalty-base…
Show more

Trevena Blogs

Trevena to Release First Quarter 2022 Financial Results on May 11, 2022

Company to host a Conference Call & Webcast at 8:00 a.m. ET CHESTERBROOK, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorder…

Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects

OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data replicate observations previously seen in a comparative study of respiratory physiology in younger subjects with OLINVYK and IV morphine …

OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting

CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a summary of activities at recent medical me…

Trevena to Participate in the Upcoming January Conferences

CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and …

Trevena Reports Second Quarter 2021 Results

Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led trial evaluating TRV027 currently enrolling COVID-19 patients Cleveland Clinic outcomes study inves…

Trevena Added to Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

CHESTERBROOK, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has been added to the small-cap Russell 20…
Show more

Trevena Frequently Asked Questions

  • When was Trevena founded?

    Trevena was founded in 2008.

  • Who are Trevena key executives?

    Trevena's key executives are Barry Shin, Mark A. Demitrack and Katrine Sutton.

  • How many employees does Trevena have?

    Trevena has 29 employees.

  • What is Trevena revenue?

    Latest Trevena annual revenue is $3.1 m.

  • What is Trevena revenue per employee?

    Latest Trevena revenue per employee is $105.8 k.

  • Who are Trevena competitors?

    Competitors of Trevena include Cadila Pharmaceuticals, CSL Behring and EMS Pharma.

  • Where is Trevena headquarters?

    Trevena headquarters is located at 955 Chesterbrook Blvd #110, Berwyn.

  • Where are Trevena offices?

    Trevena has an office in Berwyn.

  • How many offices does Trevena have?

    Trevena has 1 office.